Key result
Methylprednisolone, hydroxychloroquine, and dual-chamber permanent pacemaker implantation resolved syncope and normalized troponin-I at 3-week follow-up.
Why the study?
Cardiac complications are rare extra-glandular manifestations of primary Sjogren's syndrome, and complete atrioventricular block is an uncommon presentation.
Case Report (n=1)
No
This case highlights primary Sjögren's syndrome-related immune-mediated cardiac injury as an important differential diagnosis for unexplained complete atrioventricular block and myocardial injury after excluding obstructive coronary artery disease.
Answers are grounded in this paper and cite their sources.
Supports autoimmune evaluation in unexplained AV block with injury; leaves open whether immunosuppression alters long-term conduction outcomes in Sjögren's.
Primary Sjögren's syndrome (pSS) is a systemic autoimmune disorder predominantly involving exocrine glands; cardiac complications represent rare extra‐glandular manifestations, and complete atrioventricular block (CAVB) is uncommon. We report a 58‐year‐old female presenting with acute chest tightness and transient loss of consciousness. Her electrocardiogram showed CAVB with ventricular escape rhythm and elevated cardiac troponin‐I. Emergency coronary angiography excluded significant obstructive coronary artery disease. Positive anti‐SSA, anti‐SSB, anti‐Ro52, cardiac‐specific autoantibodies, together with minor salivary gland biopsy, confirmed pSS. She received methylprednisolone and hydroxychloroquine for immunomodulation, plus dual‐chamber permanent pacemaker implantation for persistent symptomatic conduction defects. Symptoms resolved and cardiac biomarkers normalized in short‐term follow‐up. This case alerts clinicians to pSS‐related immune‐mediated cardiac injury as a differential diagnosis for unexplained CAVB after excluding coronary artery disease.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) conducted a case report in Primary Sjögren's syndrome presenting with complete atrioventricular block and myocardial injury (n=1). Methylprednisolone, hydroxychloroquine, and dual-chamber permanent pacemaker implantation was evaluated on Resolution of clinical symptoms (chest tightness and syncope) and normalization of cardiac troponin-I. Methylprednisolone, hydroxychloroquine, and dual-chamber permanent pacemaker implantation resolved syncope and normalized troponin-I at 3-week follow-up.
Synapse has enriched 10 related papers. Consider them for comparative context: